|
 The drug, atuzaginstat, is designed to target the P. gingivalis
bacteria found in the brain of patients suffering from the memory
robbing disease.
The mid-to-late stage study tested 643 patients and did not meet
statistical significance in its goals, according to two scales
measuring disease progression.
In a group of patients with the bacteria detected in their saliva,
the drug showed 57% slowing of cognitive decline on a commonly used
test but failed to show significant benefits on another scale, which
is generally filled out by a patient's caregiver.
However, Cortexyme said the pill led to a reduction in the bacteria,
which was associated with some improved outcomes at the end of the
treatment period under the study. It plans to report the data to
regulators to determine the path forward for the drug.
[to top of second column] |
Alzheimer's treatments have come into focus since the U.S. health
regulator approved Biogen's controversial drug Aduhelm in June. The
drug is used to treat early stages of the disease.
"There's nothing that is approved for treating the really sick
patients with mild-to-moderate disease, which is where we've shown
an effect," said Cortexyme's chief medical officer Michael Detke.
(Reporting by Amruta Khandekar; Editing by Devika Syamnath)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
